Hydromac 500 Capsule contains Hydroxyurea 500 mg, an antineoplastic agent primarily used in the management of various hematologic disorders. Hydroxyurea acts by inhibiting ribonucleotide reductase, thereby interfering with DNA synthesis and exerting cytotoxic effects on rapidly dividing cells. It is commonly prescribed for conditions such as chronic myeloid leukemia, sickle cell anemia, and certain myeloproliferative disorders including polycythemia vera and essential thrombocythemia. In sickle cell anemia, Hydroxyurea increases fetal hemoglobin production, reducing the frequency of painful crises and the need for blood transfusions. The drug is administered orally, with dosage individualized based on the patient’s clinical response and hematologic parameters. Common adverse effects include myelosuppression, gastrointestinal disturbances, and dermatologic reactions; therefore, regular monitoring of blood counts and renal and hepatic function is essential during therapy. Contraindications include pregnancy, breastfeeding, and severe bone marrow suppression. Caution is advised in patients with renal or hepatic impairment. Hydromac 500 Capsule should be used under strict medical supervision to optimize therapeutic outcomes and minimize potential toxicity. Patients are advised to adhere to prescribed dosing schedules and report any adverse symptoms promptly to their healthcare provider.